Destabilization of ERBB2 transcripts by targeting 3′ untranslated region messenger RNA associated HuR and histone deacetylase-6

Molecular Cancer Research

Volumn 6, Issue 7, 2008, Pages 1250-1258

  Scott, Gary K ^a   Marx, Corina ^a   Berger, Crystal E ^a   Saunders, Laura R ^b   Verdin, Eric ^b   Schäfer, Stefan ^c   Jung, Manfred ^c   Benz, Christopher C ^a  

^a BUCK INSTITUTE FOR RESEARCH ON AGING   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HISTONE DEACETYLASE 6; HUR PROTEIN; MESSENGER RNA; DRUG DERIVATIVE; ENZYME INHIBITOR; HDAC6 PROTEIN, HUMAN; HISTONE DEACETYLASE; HU ANTIGEN; HYDROXAMIC ACID; NICOTINAMIDE; ST 71;

3' UNTRANSLATED REGION; ARTICLE; BREAST CANCER; CANCER CELL; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN BINDING; RNA STABILITY; CHEMISTRY; CYTOSOL; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PROMOTER REGION; PROTEIN TRANSPORT; TUMOR CELL LINE;

3' UNTRANSLATED REGIONS; BASE SEQUENCE; CELL LINE, TUMOR; CYTOSOL; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASES; HU PARANEOPLASTIC ENCEPHALOMYELITIS ANTIGENS; HUMANS; HYDROXAMIC ACIDS; MOLECULAR SEQUENCE DATA; NIACINAMIDE; PROMOTER REGIONS (GENETICS); PROTEIN TRANSPORT; RECEPTOR, ERBB-2; RNA STABILITY; RNA, MESSENGER;

EID: 51649126046     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-07-2110     Document Type: Article

References (26)

1. Scott GK, Marden C, Xu F, Kirk L, Benz CC. Transcriptional repression of ErbB2 by histone deacetylase inhibitors detected by a genomically integrated ErbB2 promoter-reporting cell screen. Mol Cancer Ther 2002;1:385-92.
2. Marx C, Berger C, Xu F, et al. Validated high-throughput screening of drug-like small molecules for inhibitors of ErbB2 transcription. Assay Drug Dev Technol 2006;4:273-84.
3. Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK, Benz CC. Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol 2005;45:495-528.
4. Drummond DC, Marx C, Guo Z, et al. Enhanced pharmacodynamic and antitumor properties of a histone deacetylase inhibitor encapsulated in liposomes or ErbB2-targeted immunoliposomes. Clin Cancer Res 2005;11:3392-401.
5. Barreau C, Paillard L, Osborne B. AU-rich elements and associated factors: are there unifying principles? Nucleic Acids Res 2005;33:7138-50.
6. Lopez de Silanes I, Zhan M, Lal A, Yang X, Gorospe M. Identification of a target RNA motif for RNA-binding protein HuR. Proc Natl Acad Sci U S A 2004;101:2987-92.
7. Marx C, Berger C, Benz S, Mattie M, Benz C, Scott G. Therapeutic destabilization of ErbB2 transcripts mediated by U-rich mRNA binding proteins and microRNAs. Proc Am Assoc Cancer Res 2006;47:a5616.
8. Heinonen M, Bono P, Narko K, et al. Cytoplasmic HuR expression is a prognostic factor in invasive ductal breast carcinoma. Cancer Res 2005;65:2157-61.
9. Wang W, Yang X, Kawai T, et al. AMP-activated protein kinase-regulated phosphorylation and acetylation of importin α1. J Biol Chem 2004;279:48376-88.
10. Hubbert C, Guardiola A, Shao R, et al. HDAC6 is a microtubule-associated deacetylase. Nature 2002;417:455-8.
11. Gao Y, Hubbert CC, Lu J, Lee Y-S, Lee J-Y, Yau T-P. Histone deacetylase 6 regulates growth factor-induced actin remodeling and endocytosis. Mol Cell Biol 2007;27:8637-47.
12. Zhang Y, Kwon S, Yamaguchi T, et al. Mice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normally. Mol Cell Biol 2008;28:1688-701.
13. Matthias P, Yoshida M, Khochbin S. HDAC6, a new cellular stress surveillance factor. Cell Cycle 2008;7:7-10.
14. Cabrero JR, Serrador JM, Barreiro O, et al. Lymphocyte chemotaxis is regulated by histone deacetylase 6 independently of its deacetylase activity. Mol Biol Cell 2006;17:3435-45.
15. Zhang Z, Yamashita H, Toyama T, et al. HDAC6 expression is correlated with better survival in breast cancer. Clin Cancer Res 2004;10:6962-8.
16. Benz SC, Scott GK, Marx C, Melov S, Benz CC. Histone deacetylase inhibitors accelerate decay of unique subsets of breast cancer transcripts that include ErbB2. Proc Am Assoc Cancer Res 2005;46:a5.
17. Saji S, Kawakami M, Hayashi S, et al. Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer. Oncogene 2005;24:4531-9.
18. Marx C, Yau C, Banwait S, et al. Proteasome-regulated ERBB2 and estrogen receptor pathways in breast cancer. Mol Pharmacol 2007;71:1525-34.
19. Place RF, Noonan EJ, Giardina C. HDAC inhibition prevents NF-κB activation by suppressing proteasome activity: down-regulation of proteasome subunit expression stabilizes IκBα. Biochem Pharmacol 2005;70:394-406.
20. Haggarty SJ, Koeller KM, Wong JC, Grozinger CM, Schreiber SL. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci U S A 2003;100:4389-94.
21. Scott GK, Goga A, Bhaumik D, Berger CE, Sullivan CS, Benz CC. Coordinate suppression of ERBB2 and ERBB3 by enforced expression of microRNA miR-125a or miR-125b. J Biol Chem 2007;282:1479-86.
22. Jung M, Hoffmann K, Brosch G, Loidl P. Analogues of trichostatin A, trapoxin B as histone deacetylase inhibitors. Bioorg Med Chem Lett 1997;7:1655-8.
23. Heltweg B, Jung M. A homogeneous non-isotopic assay for histone deacetylase activity. J Biomol Screen 2003;8:89-95.
24. Fischle W, Emiliani S, Hendzel MJ, et al. A new family of human histone deacetylases related to Saccharomyces cerevisiae HDA1p. J Biol Chem 1999;274:11713-20.
25. Fischle W, Dequiedt F, Hendzel MJ, et al. Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. Mol Cell 2002;9:45-57.
26. +-dependent histone deacetylases. Anal Biochem 2003;319:42-8.